DUBLIN, Feb. 5, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) a leading global biopharmaceutical company, today announced that Matthew M. Walsh has been appointed Executive Vice President and Chief Financial Officer. He will formally join Allergan later this month following a transition period from his current role as Executive Vice President, Chief Financial Officer at Catalent, Inc.
"Matt Walsh is an experienced Chief Financial Officer with a strong track record of creating value for shareholders, including 14 years as a CFO with three public companies and ten years in health care as CFO at Catalent where he led their transformation under private equity, a successful IPO and numerous acquisition and divestiture transactions, all while driving sustained organic growth. Matt brings to Allergan a unique combination of skills, including a technical background, a deep understanding of the healthcare industry, a rich experience across financial disciplines, and the ability to lead complex health care organizations," said Brent L. Saunders, Chairman and Chief Executive Officer at Allergan. "I'm pleased to welcome Matt to our team and look forward to partnering with him as we continue to drive strong financial performance and deploy our capital to increase shareholder return over the short- and long-term."
"I'm very excited to join Allergan's fast-paced, results oriented culture. I look forward to working with Brent and the leadership team to realize Allergan's long-term growth potential in the U.S. and internationally, as well as unlocking additional value through the Open Science R&D pipeline," said Matt Walsh.
Mr. Walsh currently serves as the Executive Vice President and Chief Financial Officer at Catalent, a role he assumed in 2008. Prior to joining Catalent, Walsh was President, Chief Financial Officer and Acting Chief Executive Officer at Escala Group, Inc. Prior to joining Escala, Walsh held a variety of finance leadership roles at industrial manufacturer GenTek, Inc., including Vice President-Finance & Chief Financial Officer, Vice President & Treasurer and Group Controller.
Mr. Walsh previously served on the board of directors of Multi-Color Corporation from 2015 to 2017 and Escala Group, Inc. from 2006 to 2008. While on the board of Multi-Color Corporation, he also served as Audit Committee Chairman.
Walsh is a CFA® charterholder who received a MBA from Cornell University, SC Johnson Graduate School of Management, and a Bachelor of Science in Chemical Engineering from Cornell University, College of Engineering.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
View original content with multimedia:http://www.prnewswire.com/news-releases/matthew-m-walsh-appointed-executive-vice-president-and-chief-financial-officer-of-allergan-plc-300593303.html
SOURCE Allergan plc